申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0065825A1
公开(公告)日:1982-12-01
Compounds of the formula (I) :-
and pharmaceutically acceptable salts thereof and a process for their preparation are disclosed in formula (I).
W is a 4-imidazolyl group optionally substituted in the 5-position with methyl or bromine; a 2-pyridyl group optionally substituted in the 3-position with C1-4 alkyl, C1-4 alkoxy, halogen, amino or hydroxy; a 2-thiazolyl group; a 2-guanidino-4-thiazolyl group; a 2-furanyl or 2-thienyl group optionally substituted in the 5-position with a group R1R2N(CH2)m- (where R1 and R2 which are the same or different are C1-4 alkyl or together with the nitrogen atom represent a piperidyl, pyrrolidyl or morpholinyl group, and m is an integer from 1 to 4); or a phenyl group substituted in the 3- or 4-position with a group R1R2N(CH2)m;
X is methylene (CH2) or sulphur, and
Y is methylene or, provided X is methylene and W is a substituted phenyl group, oxygen;
R3 is a carboxy or hydroxy group; R4 is hydrogen or a C1-4 alkyl group;
R5 is hydrogen, a C1-4 alkyl group, a benzyl group or with R4 a C3-5 alkylene group; and
R6 is hydrogen or a C1-4 alkyl group. The compounds of the invention are histamine H2-antagonists.
式 (I) :- 的化合物及其药学上可接受的盐类以及它们的制备方法已被公开。
及其药学上可接受的盐类,以及它们的制备方法见式 (I)。
W 是在 5 位上任选被甲基或溴取代的 4-咪唑基;在 3 位上任选被 C1-4 烷基、C1-4 烷氧基、卤素、氨基或羟基取代的 2-吡啶基;2-噻唑基;2-胍基-4-噻唑基;2-呋喃基或 2-噻吩基,可选择在 5 位被基团 R1R2N(CH2)m- 取代(其中 R1 和 R2 相同或不同,均为 C1-4 烷基或与氮原子一起代表哌啶基、吡咯烷基或吗啉基,且 m 为 1 至 4 的整数);或在 3 位或 4 位被基团 R1R2N(CH2)m 取代的苯基;
X 是亚甲基(CH2)或硫,以及
Y 是亚甲基,如果 X 是亚甲基,W 是被取代的苯基,则 Y 是氧;
R3 是羧基或羟基; R4 是氢或 C1-4 烷基;
R5 是氢、C1-4 烷基、苄基或与 R4 同为 C3-5 亚烷基;以及
R6 是氢或 C1-4 烷基。本发明的化合物是组胺 H2- 拮抗剂。